Mumbai-based API manufacturer of anesthetics, anti-histamines & anti-asthmatics exported to 120+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 15 | 15 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 134 | 254 | 600 | 683 | 799 | 981 | 1.1k | 1.2k |
| Borrowings | 82 | 72 | 27 | 22 | 5 | 5 | 5 | 5 |
| Other Liabilities | 105 | 105 | 92 | 98 | 101 | 110 | 116 | 154 |
| Total Liabilities | 336 | 445 | 735 | 820 | 921 | 1.1k | 1.2k | 1.4k |
| AssetsFixed Assets | 99 | 100 | 190 | 262 | 310 | 453 | 458 | 689 |
| CWIP | 40 | 79 | 43 | 68 | 149 | 148 | 172 | 36 |
| Investments | 0 | 0 | 0 | 25 | 64 | 63 | 57 | 99 |
| Other Assets | 197 | 267 | 502 | 466 | 399 | 448 | 516 | 534 |
| Total Assets | 336 | 445 | 735 | 820 | 921 | 1.1k | 1.2k | 1.4k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 49 | 117 | 76 | 49 | 64 | 113 | 165 | — |
| Cash from Investing | 5 | -25 | -47 | -60 | -124 | -174 | -152 | — |
| Cash from Financing | -50 | -29 | -15 | 150 | -10 | -22 | -8 | — |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 54 | 92 | 29 | -11 | -44 | -32 | 2 | — |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (23.1×) and current (35.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 32.4% growth and a 23× exit, ₹932 only delivers your return if you pay ₹1,155. The price is currently baking in 27% growth.
EPS grows 32.4%/yr for 5 years, then fades to 6% over 2, exits at 23×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 32.4% | 34.40 |
| FY28 | 32.4% | 45.54 |
| FY29 | 32.4% | 60.30 |
| FY30 | 32.4% | 79.83 |
| FY31 | 32.4% | 105.70 |
| FY32 | 19.2% ·fade | 126.00 |
| FY33 | 6.0% ·fade | 133.56 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.